These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18358605)

  • 21. The chaperone activity of α-synuclein: Utilizing deletion mutants to map its interaction with target proteins.
    Rekas A; Ahn KJ; Kim J; Carver JA
    Proteins; 2012 May; 80(5):1316-25. PubMed ID: 22274962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.
    Mirzaei H; Schieler JL; Rochet JC; Regnier F
    Anal Chem; 2006 Apr; 78(7):2422-31. PubMed ID: 16579629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel mechanism of interaction between alpha-synuclein and biological membranes.
    Kim YS; Laurine E; Woods W; Lee SJ
    J Mol Biol; 2006 Jul; 360(2):386-97. PubMed ID: 16762368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers.
    Brucale M; Sandal M; Di Maio S; Rampioni A; Tessari I; Tosatto L; Bisaglia M; Bubacco L; Samorì B
    Chembiochem; 2009 Jan; 10(1):176-83. PubMed ID: 19067456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
    Park JY; Paik SR; Jou I; Park SM
    Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
    Paleologou KE; Irvine GB; El-Agnaf OM
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease.
    Bharathi ; Rao KS
    Biochem Biophys Res Commun; 2007 Jul; 359(1):115-20. PubMed ID: 17531952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
    Luk KC; Hyde EG; Trojanowski JQ; Lee VM
    Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein.
    Smith DP; Tew DJ; Hill AF; Bottomley SP; Masters CL; Barnham KJ; Cappai R
    Biochemistry; 2008 Feb; 47(5):1425-34. PubMed ID: 18179253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains.
    Stöckl M; Fischer P; Wanker E; Herrmann A
    J Mol Biol; 2008 Feb; 375(5):1394-404. PubMed ID: 18082181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.
    Gerard M; Debyser Z; Desender L; Baert J; Brandt I; Baekelandt V; Engelborghs Y
    J Neurochem; 2008 Jul; 106(1):121-33. PubMed ID: 18346205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.
    Foulds PG; Mitchell JD; Parker A; Turner R; Green G; Diggle P; Hasegawa M; Taylor M; Mann D; Allsop D
    FASEB J; 2011 Dec; 25(12):4127-37. PubMed ID: 21865317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation.
    Binolfi A; Lamberto GR; Duran R; Quintanar L; Bertoncini CW; Souza JM; Cerveñansky C; Zweckstetter M; Griesinger C; Fernández CO
    J Am Chem Soc; 2008 Sep; 130(35):11801-12. PubMed ID: 18693689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.
    Murray IV; Giasson BI; Quinn SM; Koppaka V; Axelsen PH; Ischiropoulos H; Trojanowski JQ; Lee VM
    Biochemistry; 2003 Jul; 42(28):8530-40. PubMed ID: 12859200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein.
    Wersinger C; Jeannotte A; Sidhu A
    Eur J Neurosci; 2006 Dec; 24(11):3141-52. PubMed ID: 17156375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study.
    Bharathi ; Indi SS; Rao KS
    Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages.
    Ichibangase T; Saimaru H; Takamura N; Kuwahara T; Koyama A; Iwatsubo T; Imai K
    Biomed Chromatogr; 2008 Mar; 22(3):232-4. PubMed ID: 17939164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.
    Brandt I; Gérard M; Sergeant K; Devreese B; Baekelandt V; Augustyns K; Scharpé S; Engelborghs Y; Lambeir AM
    Peptides; 2008 Sep; 29(9):1472-8. PubMed ID: 18571285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.